China's National Medical Products Administration accepted the marketing application of Huadong Medicine's (SHE:000963) unit, Hangzhou Sino-American East China Pharmaceutical, for Roflumilast Cream, according to a Saturday filing on the Shenzhen bourse.
The shares rose less than 1% during Monday's midday trade.
The overseas-manufactured drug, which has the trade name Zoryve, treats plaque psoriasis in patients aged 6 years old and above.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments